MNG324
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.377
- MYC_TARGETS_V1+0.251
- UNFOLDED_PROTEIN_RESPONSE+0.223
- MYC_TARGETS_V2+0.211
- PROTEIN_SECRETION+0.120
- SPERMATOGENESIS+0.114
- KRAS_SIGNALING_DN+0.103
- ESTROGEN_RESPONSE_EARLY+0.073
- CHOLESTEROL_HOMEOSTASIS+0.072
- ANDROGEN_RESPONSE+0.030
Top 10 suppressed
- ANGIOGENESIS-0.526
- IL6_JAK_STAT3_SIGNALING-0.508
- ALLOGRAFT_REJECTION-0.468
- INTERFERON_GAMMA_RESPONSE-0.454
- INTERFERON_ALPHA_RESPONSE-0.437
- TNFA_SIGNALING_VIA_NFKB-0.430
- INFLAMMATORY_RESPONSE-0.369
- COMPLEMENT-0.304
- GLYCOLYSIS-0.295
- G2M_CHECKPOINT-0.292
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | a277c487-2d13-460f-a0d8-26acac1657d0 | — | — | 0.804 |
| 2 | ERR2208968 | — | — | 0.801 |
| 3 | SRR8613793 | — | B | 0.797 |
| 4 | R274 | — | — | 0.793 |
| 5 | MBCProject_0343_T1_RNA | — | B | 0.792 |
| 6 | TCGA-OR-A5LB-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.789 |
| 7 | b98a06c6-3b43-4749-98cf-b28f4ba06845 | — | — | 0.787 |
| 8 | SRR10899984 | — | — | 0.783 |
| 9 | BS_DGTPWJ59 | Neurocytoma | — | 0.782 |
| 10 | SAMN03290937 | — | — | 0.779 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.377 | Cobimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.251 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.223 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.211 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.120 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.114 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.103 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.073 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.072 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.030 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.010 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.001 | Inavolisib | — uncovered |